31 December 2012 | News | By BioSpectrum Bureau
Emergent BioSolutions to market nex-gen pandemic influenza vaccine
Emergent BioSolutions and VaxInnate sign pandemic influenza vaccine deal
Singapore: Emergent BioSolutions has signed a license agreement with VaxInnate under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the US. The product candidate, a recombinant vaccine, has the potential to be produced quickly, at high yields and in a cost-effective manner.
This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced R&D Authority (BARDA), which established Emergent as a Center for Innovation in Advanced Development and Manufacturing (Center) in June 2012.
VaxInnate will continue to develop its pandemic influenza vaccine candidate under its current BARDA contract and Emergent will manufacture the pandemic influenza vaccine candidate using flexible manufacturing technology.
As a center, Emergent is required to acquire intellectual property rights for a pandemic influenza vaccine candidate and to obtain facility licensure to manufacture a pandemic influenza vaccine funded by Biomedical Advanced Research and Development Authority of the US Department of Health and Human Services.